Concordance Between Buccal Cavity Swab and Nasopharyngeal Swab for SARS-CoV-2 (COVID-19) Detection by RT-PCR and ELISA

Overview

Nasopharyngeal Swabs (NPS) used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection can cause mild to severe discomfort in addition to increasing the risk of transmission. The present study evaluates Test At Home's proprietary self-collection method based on a chewable buccal cavity swab ("lollipop") that stimulates oral fluid collection. The novel method is compared against a contemporary nasal swab collected by a qualified healthcare worker.

Full Title of Study: “Evaluating the Use of Flavour-stimulated Oral Fluids Collection for Severe Acute Respiratory Syndrome Coronavirus 2 Detection by Reverse Transcriptase Polymerase Chain Reaction and Enzyme Linked Immunosorbent Assay – a Concordance Study.”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 31, 2021

Detailed Description

Nasopharyngeal Swabs (NPS) are used to test for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. For this, a swab is inserted deep into the back of the nose to collect a sample. It can cause discomfort for most people. It also increases the risk of transmission and other challenges. The present study aims to develop a more convenient method of collecting samples for COVID-19 testing. The study is based on the hypothesis that saliva collection using the proprietary flavour-stimulated 'Lollipop' swab (LPS) can be a more viable alternative to NPS. The study aims to establish the comparative efficacy of SARS-Cov-2 infection assessment using Test At Home's proprietary "lollipop" buccal cavity swab (LPS) that simulates oral fluid collection via flavouring and mastication (self-collection) using the contemporary nasal swab collection (by health worker) as standard. For the present study, 300 pairs of matched nasopharyngeal swab (NPS) (health care worker collected) and simulated oral fluid specimens (self-collected) will be obtained from 150 Coronavirus Disease -19 (COVID-19) positive patients and 150 COVID 19 negative individuals. Test Method 1: Self-collected Test At Home's proprietary "lollipop" buccal cavity swab with Viral Transport Medium (VTM) will be evaluated using the Standard 'TaqPath™' COVID-19 Conformité Européenne – In Vitro Diagnostic (CE-IVD) Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) which is approved by the Indian Council of Medical Research (ICMR) Test Method 2: Self-collected Test At Home's proprietary "lollipop" buccal cavity swab with VTM will be evaluated using National University of Singapore (NUS) developed Enzyme Linked Immunosorbent Assay (ELISA) Method. Active Comparator : Health worker collected Nasopharyngeal Swab (NPS) with VTM which will be evaluated using the Standard TaqPath™ COVID-19 CE-IVD RT-PCR which is approved by the Indian Council of Medical Research (ICMR). The diagnostic performance of using NPS and Oral fluids will be statistically compared to determine concordance of positive and negative findings and establish the performance characteristics of the Test Methods.

Interventions

  • Diagnostic Test: Test At Home’s Proprietary “Lollipop” Buccal Cavity Swab
    • Self-collected Test At Home’s proprietary “Lollipop” Buccal Cavity Swab with VTM.

Arms, Groups and Cohorts

  • COVID Positive
    • Individuals who have recently tested positive for COVID19 by RTPCR, with active infection.
  • COVID Negative
    • Individuals who have recently tested negative for COVID19 by RTPCR.

Clinical Trial Outcome Measures

Primary Measures

  • Concordance between buccal cavity swab and contemporary nasal swab.
    • Time Frame: Baseline / Day 0 (At first collection)
    • Three-way concordance of SARS-Cov-2 infection assessment between Test At Home’s “Lollipop” buccal cavity swab (assessed by RTPCR and ELISA) and contemporary nasal swab (assessed by RTPCR).

Participating in This Clinical Trial

Inclusion Criteria

1. Males and Females 2. Adults 3. Known COVID-19 positive by RTPCR (with active infection) OR Known COVID-19 negative by RTPCR (tested within 7 days) 4. Provision of Informed Consent 5. Willing to provide Nasopharyngeal Swab as well as Buccal Cavity Swab Exclusion Criteria:

1. Pediatric patients. 2. Inability to provide Informed Consent. 3. Inability to provide Nasopharyngeal Swab and / or Buccal Cavity Swab.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Investigator Details

  • Lead Sponsor
    • Datar Cancer Genetics Limited
  • Collaborator
    • Test At Home Pte. Ltd
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Vivek Manoharan, PhD, Principal Investigator, Test At Home Pte. Ltd., Singapore – India.
    • Paul Macary, PhD, Principal Investigator, National University of Singapore
    • Saket Jhajharia, PhD, Principal Investigator, Test At Home Pte. Ltd., Singapore – India
    • Terence Tan, MBBS, Principal Investigator, Test At Home Pte. Ltd., Singapore – India.
    • Vineet Datta, MD, Principal Investigator, Datar Cancer Genetics Limited, United Kingdom – India
    • Kanupriya Batra, MBA, Principal Investigator, Test At Home Pte. Ltd., Singapore – India.
  • Overall Contact(s)
    • Vineet Datta, MD, +919911110457, drvineetdatta@datarpgx.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.